Skip to main content

Table 1 Patients characteristic

From: ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk “BCG failure” non muscle invasive bladder cancer: 3 years follow-up outcomes

N° of patients 26
Age, mean years (range) 66 (49-79)
Gender, n° of patients (%)
 Male 21 (80.8%)
 Female 5 (19.2%)
Months of follow-up, median 36
Histopathological stage, n° of patients (%)
 TaG3 4 (15.4%)
 T1G3 14 (53.8%)
 Cis 4 (15.4%)
 Ta/T1G3 + Cis 4 (15.4%)
Time from first diagnosis, months range 3-9
\